Alchemia locks in new funding as it preps for oncology spin-off
This article was originally published in Scrip
Executive Summary
The Australian drug discovery firm Alchemia has raised A$15 million ($15.5 million) in a placement to domestic and US institutional investors, part of which it will use to support the planned spin-off and listing of its cancer-related subsidiary Alchemia Oncology.